drugset / Trial / NCT03050047
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
Timeline
- Start
- 2016-08-30
- Primary completion
- 2017-07-01
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCD-100 | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | BCD-100 | Monoclonal antibody | 1 mg/kg | — |
| Subject | BCD-100 | Monoclonal antibody | 3 mg/kg | — |
| Subject | BCD-100 | Monoclonal antibody | 10 mg/kg | — |